The National Institute for Allergy and Infectious Diseases has awarded Jeffrey Glenn, MD, PhD, professor of hepatology and gastroenterology and of microbiology and immunology, $69 million...
Read More
A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.
Read More 
The Antiviral Program for Pandemics (APP) aims to develop safe and effective antivirals to combat SARS-CoV-2, the virus that causes COVID-19, as well as to build sustainable platforms for targeted drug discovery and development of a robust pipeline of antivirals against viruses with pandemic potential.
Read More 
Chris has a proven record of accomplishment delivering results to pharmaceutical and scientific organizations, including 33 years of management experience at Eli Lilly and Company, within Lilly Research Laboratories (LRL), 3.5 years in a global leadership role at IQVIA, and now as Deputy Director and COO of a significant NIH/NIAID research grant at Stanford University Medical School.
Over the years, Chris has served as a leader of multiple global teams in drug development and R&D Operations, representing her organizations in multiple external settings, including scientific, academic, drug development and R&D Operations forums.
In, December 2017, Chris retired from Lilly as Sr. Director, External Sourcing, leading an enterprise-wide R&D operations group that partnered with LRL functions to assess, on-board, and govern third party organizations across the entire drug development value chain, from pre-clinical, through clinical, regulatory, safety, health outcomes, product and device development, and diagnostics. The division consolidated both corporate and external requirements to deliver high-quality, risk-based, third party governance, oversight and alliance management for the LRL Development organization.
In February 2019, Chris joined IQVIA as the Vice-President of Strategy & Operations for DSSR, and subsequently moved in the role of Vice-President, Global Regulatory Affairs.
Specialties: Pharmaceutical Development, R&D Operations, Molecule Submission/Approval/Launch, Product Lifecycle Planning and Development, R&D Business Systems design and delivery. Third Party Management, Women's Leadership Development.
Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.
Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.
He is an international authority on developing novel antiviral therapeutics.
